Last reviewed · How we verify
Havrix (HAV)
Havrix is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.
Havrix is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Prevention of hepatitis A infection in adults and children ≥12 months of age, Post-exposure prophylaxis for hepatitis A.
At a glance
| Generic name | Havrix (HAV) |
|---|---|
| Sponsor | Pfizer |
| Drug class | Inactivated viral vaccine |
| Target | Hepatitis A virus antigen |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Havrix contains inactivated (killed) hepatitis A virus antigen, which triggers both humoral and cellular immune responses without causing disease. The vaccine induces the production of anti-HAV antibodies that provide long-term protection against hepatitis A infection. A single dose provides protection in approximately 95% of recipients within 2 weeks, with booster doses extending immunity to 20+ years.
Approved indications
- Prevention of hepatitis A infection in adults and children ≥12 months of age
- Post-exposure prophylaxis for hepatitis A
Common side effects
- Injection site soreness
- Headache
- Fatigue
- Fever
- Myalgia
- Nausea
Key clinical trials
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd) (PHASE4)
- Trial of Antibody Responses by Vitamin Supplementation (PHASE1)
- To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A) (PHASE3)
- Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents (PHASE3)
- A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Havrix (HAV) CI brief — competitive landscape report
- Havrix (HAV) updates RSS · CI watch RSS
- Pfizer portfolio CI